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Here, we show that inhibition ofmechanistic/mammalian Target of Rapamycin (mTOR) complex 1 (mTORC1) by
rapamycin or theWnt-β-catenin signalling activator TWS119 in activated human naive T cells leads to the induc-
tion of TSCM cells. We show that these compounds switch T cell metabolism to fatty acid oxidation as favoured
metabolic programme for TSCM cell generation. Of note, pharmacologically induced TSCM cells possess superior
functional features as a long-term repopulation capacity after adoptive transfer. Furthermore, we provide in-
sights into the transcriptome of TSCM cells.
Our data identify a mechanism of pharmacological mTORC1 inhibitors, allowing us to confer stemness to human
naive T cells whichmay be signiﬁcantly relevant for the design of innovative T cell-based cancer immunotherapies.
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Rapamycin1. Introduction
Similar to solid organs, T cells have been suggested to harbour a self-
renewing stem cell-like population which permanently replenishes the
pools of further differentiated effectors. Since central memory T (TCM)
cells have been shown to repopulate the effector memory T (TEM) cell
and effector T (TEFF) cell pools in response to antigen stimulus (Graef
et al., 2014;Wherry et al., 2003), they were thus far regarded as “mem-
ory stem cells”. However, further complexity was brought to this view
by the recent discovery of an additional memory T cell subset, which
was able to mediate a prolonged immune response in a mouse model
of graft-versus-host disease (GVHD) (Zhang et al., 2005). This memory
T cell subset, termed stem cell-like memory T (TSCM) cells, has been re-
cently described in mice, non-human primates and in humans
(Gattinoni et al., 2009, 2011; Lugli et al., 2013). As least differentiated
distinct memory T cell subset, TSCM cells have been put at the top ofunology Group, Ludwig Cancer
linges, Vaud, Switzerland.
. This is an open access article underthe hierarchy of all memory T cell subsets in a model of progressive T
cell differentiation, leading from naive T (TN) cells over TSCM cells and
TCM cells to TEM cells and TEFF cells. This position of TSCM cells between
TN cells and memory T cells is phenotypically reﬂected by the expres-
sion of activation markers as the death receptor CD95, the β-chain of
the IL-2 receptor (CD122) or the adhesion molecule CD58 on naive-
appearing CCR7+, CD45RA+, CD45RO− T cells (Gattinoni et al.,
2011). After genetic modiﬁcation into mesothelioma-speciﬁc CAR T
cells, adoptively transferred TSCM cells were shown to mediate an im-
proved anti-tumour immune response compared to TN cells, TCM cells
and TEM cells in a humanized mouse model (Gattinoni et al., 2011),
which seems to depend on a more efﬁcient TSCM cell engraftment and
long-term persistence in the host which enables them, while self-
renewing, to constantly differentiate into TEFF cells and, thereby, to
completely eradicate the tumour.
Because of these ideal characteristics there is a quest for the signal-
ling pathwayswhichmediate TSCM cell induction. Once identiﬁed, phar-
macological interference with these signalling pathways could be used
for their targeted induction in anti-tumour immunotherapy. In this re-
gard, the in vitro activation of CD8+ TN cells in the presence of thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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which inhibits glycogen synthase kinase-3β (GSK-3β) by phosphoryla-
tion, has been suggested to arrest TN cell differentiation and to generate
TSCM cells (Gattinoni et al., 2011). However, the interpretability of these
data remains inconclusive, since the starting pool of TN cells also
contained TSCM cells so that an expansion effect of TWS119 on pre-
existing TSCM cells or TSCM cell self-maintaining factors cannot be ex-
cluded. Moreover, increasing evidence suggests that T cell metabolism
is an important determinant of T cell differentiation (Pearce et al.,
2009), which raises the possibility that metabolic integrators like
mechanistic/mammalian Target Of Rapamycin (mTOR) kinase might
represent pharmacological targets for the enrichment of a desired
differentiation-deﬁned T cell population (Araki et al., 2009; Diken
et al., 2013; Rao et al., 2010; Turner et al., 2011), thereby potentially
favouring the induction of qualitatively improved memory T cells.
We, therefore, set out to investigatewhethermTORC1 inhibitors like
rapamycin would be relevant for the generation of human TSCM cells
and whether a cross-talk between mTOR and Wnt signalling would
exist. Moreover, since current knowledge on the generation and charac-
terization of TSCM cells remains limited to CD8+ TSCM cells, apart from
their phenotypic deﬁnition, CD4+ TSCM cells remain uninvestigated.
The characterization of CD4+ TSCM cells seems to be of great impor-
tance all the more, as the role of CD4+ T cells as broad orchestrators
of the immune response receives growing attention in anti-tumour im-
munotherapy (Kamphorst and Ahmed, 2013; Muranski and Restifo,
2009). In the present study, therefore, focus was put on the induction
and characterization of CD4+ TSCM cells, nevertheless testing the rele-
vance of our ﬁndings on TSCM cell induction also for CD8+ TSCM cells.
Here,we revealed the inhibition ofmTORC1with simultaneously ac-
tivemTORC2 signalling as themolecularmechanism inducing TSCM cells
and that TSCM cell induction takes place in complete independence from
Wnt signalling. We furthermore present insights into the
transcriptomes of naturally occurring and pharmacologically induced
CD4+ TSCM cells, the in vivo survival and repopulation capacity of phar-
macologically induced CD4+ TSCM cells and the metabolic regulation of
CD4+ TSCM cell generation. Taken together, our ﬁndings are of direct
relevance for the design of improved anti-tumour immunotherapies.
2. Materials & Methods
2.1. Human T Lymphocytes
Peripheral bloodmononuclear cells (PBMCs) were isolated by densi-
ty centrifugation over a Ficoll-Paque gradient (Lymphoprep™) from
buffy coats of healthy human female and male blood donors, obtained
from the Vaud blood transfusion service. Experiments were performed
in accordance to the guidelines of the Ethics Commission of the UNIL.
Prior to sorting, PBMCswere puriﬁedwith CD3, CD4or CD8Dynabeads®
(Invitrogen™).
2.2. Animal Experiments
Animal experimentswere performed in accordance to the guidelines
of the Ethics Commission of the UNIL. In vitro experiments and assess-
ment of TSCM cell frequencies were performed with female Raptor
(CD4-Cre), β-/γ-catenin (Vav-Cre) KO mice and their corresponding
WT forms. Adoptive T cell transfer was conducted with female
NOD.Cg-PrkdcscidIl2rgtm1WjI/SzJ mice (NSG).
2.3. Cell Culture
T cells were cultured in RPMI-1640 supplemented with 8% heat
inactivated, pooled human serum or 10% foetal calf serum, 50 IU/ml
penicillin, 50 μg/ml streptomycin, 4 mM L-glutamine, 1% (v/v) non-
essential amino acids and 50 μM 2-mercaptoethanol. Sorted TN cells
were primed with anti-CD3/CD28 beads (Invitrogen) or OKT3/anti-CD28 antibody (in house, derived from hybridoma cells) and IL-2
(Proleukin®, Roche Pharma AG). Pathway interfering drugs were
TWS119 (Cayman Chemical), rapamycin (LC Laboratories), PP242
(Chemdea), KU-0063794 (Chemdea), Indirubin-3-monoxime (Sigma-
Aldrich), SB216763 (Sigma-Aldrich) and recombinant human Wnt3A
(R&D Systems).
2.4. Flow Cytometry
Flow cytometry acquisition was performed with a Gallios™
(Beckman Coulter) or a LSR II ﬂow cytometer (BD Biosciences). Cell
sorting was conducted with a FACS Aria (BD Biosciences) or a MoFlo®
Astrios™ cell sorting instrument (Beckman Coulter). Flow cytometry
analysis was performed with FlowJo software (Version 7.6.5, Treestar).
Antibodies and staining panels are listed in the Supplemental Exper-
imental Procedures.
2.5. Phospho-speciﬁc Flow Cytometry
1,000,000 TN cells were sorted per condition. After activation with
anti-CD3/CD28 beads (1:1 bead/cell ratio) in the presence of TWS119
(5 μM) or rapamycin (100 nM) for 4 h, TN cells were harvested, ﬁxed
and incubated with ice-cold 50% methanol for membrane perme-
abilization. Primary antibodies were pS6 ribosomal protein (Ser235/
236), pGSK-3β (Ser9), pAKT (Ser473), p4EBP1 (Ser65), p4EBP1
(Thr37/46) (all from Cell Signaling). The secondary antibody was
Alexa Fluor 647 goat anti rabbit IgG (Life Technologies).
2.6. Western Blot Analysis
For Western blot analysis activated (4 h in presence of indicated
drugs) natural (n) CD4+ TN cells were washed in ice-cold PBS and
lysed in RIPA buffer containing protease inhibitor and sodium
orthovanadate (Santa Cruz Biotechnologies). Proteins were separated
by 4% to 12% polyacrylamide gel and transferred to a polyvinylidene
diﬂuoride membrane (Millipore). Membranes were blocked with
Odyssey® blocking buffer (LI-COR Biosciences) and immunoblotted
with the primary antibodies pS6 ribosomal protein (Ser235/236),
pAKT (Ser473), β-actin (all from Cell Signaling) followed by infrared
secondary antibodies. Bands from immunoreactive proteins were visu-
alized by an Odyssey® infrared imaging system (LI-COR Biosciences).
2.7. RNA Sequencing
RNA sequencing was conducted with nCD4+ TN, TSCM and TCM cells
from 4 healthy human donors. Additionally, TWS119- and rapamycin-
induced TSCM cellswere resorted after 14days of nCD4+TN cell priming
from the same donors. RNA was puriﬁed with Arcturus PicoPure RNA
Isolation kit (Biosystems/Applied Life Technologies). An amount of
10 ng total RNA was ampliﬁed with the SMARTer Ultra Low RNA Kit
for Illumina Sequencing (Clontech Laboratories, Inc.) and the Advantage
2 PCR Kit (Clontech Laboratories, Inc.). The cDNA from the ampliﬁcation
reactions was sheared with a Covaris ultrasonicator (Covaris, Inc.) and
sequencing libraries were generated with a Truseq DNA kit (Illumina,
Inc.). Libraries were sequenced at 100 nucleotides single read mode
on an Illumina HiSeq 2000 instrument.
2.8. Adoptive T Cell Transfer
Adoptive T cell transfer was conducted by tail vein injection of
200,000 rapamycin-induced CD4+ TSCM cells and equal numbers of
CD4+TN-like and TCM-like cells. Controlmice received an equal volume
of culture medium. Lymphocytes from lung and liver were isolated by
Percoll™ technique.
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30,000 rapamycin-induced CD4+ TSCM cells and equal numbers of
TN- and TCM-like cells were labelled for 6 days with carboxyﬂuorescein
succinimidyl ester (CFSE, Life Technologies) (ﬁnal concentration:
0.25 μM) and expanded in presence of IL-2 (50 IU/ml). Dilution of
CFSE (488 nm) was assessed by ﬂow cytometry. The proliferation
index was calculated with ModFit LT software (Version 3.3.11, Verity
Software House, Inc.).2.10. MMP
Assessment of MMP was performed with TMRE — Mitochondrial
Membrane Potential Assay Kit (Abcam®). 5,000,000 nCD4+ T cells
and equal numbers of T cells derived from nCD4+ TN cells, which
have been activated for 14 days in presence of rapamycin (100 nM),
were used. T cells were incubated with 100 nM tetramethylrhodamine,
ethyl ester (TMRE) for 30 min at 37 °C in the water bath. Carbonyl
cyanide-4-(triﬂuoromethoxy)phenylhydrazone (FCCP, 100 μM) was
added during acquisition.2.11. 2-NBDG Uptake
2-[N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose
(2-NBDG, Invitrogen) uptake was carried out with 5,000,000 nCD4+
T cells and equal numbers of T cells, derived from nCD4+ TN cells,
which have been activated for 14 days in presence of rapamycin
(100 nM). T cells were incubated for 15 min at 37 °C in glucose-free
Krebs-Ringer Hepes buffer (Hepes 50 mM, NaCl 137 mM, KCl 4.7 mM,
CaCl2 1.85 mM, MgSO4 1.3 mM, BSA 0.1% w/v, pH 7.4). T cells were
pelleted, washed and incubated with 100 μM 2-NBDG at 37 °C in the
water bath prior to measuring ﬂuorescence by ﬂow cytometry.2.12. Assessment of ECAR and OCR
For extracellular acidiﬁcation rate (ECAR) and oxygen consumption
rate (OCR) measurements we used an XF24 extracellular analyser
(Seahorse™ Bioscience). TN (750,000 per well) and TSCM cells (200,000
perwell) have been immobilized using CellTak™ agent (BDBiosciences).
T cells were kept in non-buffered assay medium (KHB with 25 mM glu-
cose, 1 mM sodium pyruvate, 2 mM glutamine for ECAR assessment or
2.5 mM glucose and 1.5 mM carnitine for OCR measurement) and incu-
bated in a non-CO2 incubator for 60 min at 37 °C prior to analysis. Anti-
CD3/CD28 beads, TWS119, rapamycin, oligomycin and palmitate were
added prior to or during the analysis at the indicated time points and
concentrations. ECAR and OCR were calculated using Seahorse™ Biosci-
ence proprietary software.2.13. Statistical Analysis
2.13.1. Flow Cytometry
Statistical analysis was performed with Prism software (Version 6,
GraphPad), using a paired t-test.2.13.2. RNA Sequencing
The raw sequencing reads were trimmed with Trim Galore! (http://
www.bio-informatics.babra-ham.ac.uk/projects/trim_galore/) (Version
0.3.3), using cutadapt (Version 1.2.1) to remove low-quality bases
(quality Phred score cut-off 15) and remaining adaptor sequences. Fur-
ther information is provided in the Supplemental Experimental Proce-
dures. For all analyses, a p-value (adj.) less than 0.05 was considered
as statistically signiﬁcant and labelled with *, less than 0.01 with **,
less than 0.001 with *** and less than 0.0001 with ****.3. Results
3.1. TWS119 and Rapamycin Induce Phenotypic TSCM Cells
To assess the inﬂuence ofWnt andmTOR on human TSCM cell gener-
ation, highly puriﬁed CD4+ and CD8+ TN cells (natural (n)) were
sorted ex vivo (Fig. S1a) and activated with anti-CD3/CD28 beads (1:1
bead/cell ratio) and IL-2 (300 IU/ml) in the presence of the Wnt activa-
tor TWS119 (5 μM) or the mTOR inhibitor rapamycin (100 nM).
After 14 days, nCD4+ TN cells, primed in the presence of TWS119 or
rapamycin, formed two lymphocyte populations, a small-sized and a
large-sized one, based on forward scatter/side scatter (FSC/SSC) pro-
ﬁles. In contrast, nCD4+ TN cells which have been cultured in the ab-
sence of TWS119 or rapamycin did not generate the small-sized
lymphocyte population (Fig. 1a). Phenotypic analysis revealed that the
small-sized lymphocyte population mainly consists of T cells with a
CCR7+, CD45RA+ TN-like phenotype and a small fraction of cells
with a CCR7+, CD45RA- TCM-like phenotype. Of note, the TN-like popu-
lation displayed phenotypic CD95+, CD58+ TSCM cells whichwere sig-
niﬁcantly increased in absolute cell numbers in comparison to TCM-like
cells (Fig. 1b, Fig. S1b and Table 1), suggesting TWS119 and rapamycin
as speciﬁc inducers of TSCM cells. These cells co-expressed high levels
of the CD62L selectin (not shown).We then subdivided the TN-like pop-
ulation into a CCR7+, CD45RAintermediate “transition zone” (TZ) and a
CCR7+, CD45RAhigh “rand zone” (RZ) to investigate whether TSCM
cells would be preferentially located in a distinct region of the TN-like
population. Interestingly, this was indeed the case, since the TZ contains
higher frequencies of phenotypic TSCM cells compared to the RZ
(Fig. 1B), in line with a model of progressive T cell differentiation, posi-
tioning TSCM cells in between TN cells and TCM cells. The large-sized lym-
phocyte population did not show signiﬁcant differences in cellular
composition upon drug treatment with or without TWS119 or
rapamycin and exhibited a mixture of TN-like, TCM-like and TEM-like
(CCR7−, CD45RA−) cells (Table S1), suggesting the small-sized lym-
phocyte population as place of CD4+ TSCM cell induction.
To further explore the mechanism of TSCM cell induction by TWS119
and rapamycin,we next tested the alternativeWnt activators Indirubin-
3-monoxime (4 μM) and Wnt3A (10 nM) as well as the ATP-
competitive mTOR inhibitors PP242 and KU-0063794. PP242 and KU-
0063794 used at low concentrations (100 nM) inhibit mTORC1, while
at higher concentrations (1 μM) they also block mTORC2 (data not
shown). Supporting our ﬁnding with rapamycin, 14 days of nCD4+
TN cell priming in the presence of low-concentrations (100 nM) PP242
or KU-0063794 also triggered the formation of a small-sized lympho-
cyte population with phenotypic TSCM cells (Fig. 1c and Fig. S1d). How-
ever, surprisingly in contrast to TWS119, the alternative Wnt activators
Indirubin-3-monoxime andWnt3A did not generate a small-sized lym-
phocyte population (Fig. 1c), questioning an involvement ofWnt signal-
ling in TSCM cell induction.
Testing these observations for CD8+ TSCM cell induction, priming of
highly puriﬁed nCD8+TN cells for 14 days in thepresence of TWS119or
rapamycin, in comparison to drug absence or priming in the presence of
Indirubin-3-monoxime (4 μM), resulted in increased frequencies of TN-
like cells, displaying a population of phenotypic CD95+, CD58+ TSCM
cells (Fig. S1c), suggesting a common pharmacological mechanism of
rapamycin and TWS119 also for CD8+ TSCM cell induction. Thus,
taken together, inhibitors of mTOR induce phenotypic CD4+ and
CD8+ TSCM cells, whereas, apart from TWS119, other Wnt activating
drugs fail in doing so.
3.2. TWS119 Inhibits mTORC1
To test the hypothesis about a commonpharmacologicalmechanism
of TWS119 and rapamycin in TSCM cell induction, the phosphorylation of
GSK-3β (pGSK-3β, read-out for Wnt activity) and the phosphorylation
of S6 ribosomal protein (pS6, read-out for mTORC1 activity) were
Fig. 1.TWS119 andrapamycin inducephenotypic TSCM cells. (a)Highlypuriﬁed (TSCM cell-freed)humannCD4+TN cells activated for 14days in thepresence of TWS119 (5 μM)or rapamycin
(100 nM) form a small-sized lymphocyte populationwhich is not induced in the absence of TWS119 or rapamycin (red arrows). n= 5. (b) The small-sized lymphocyte populations induced
by TWS119 or rapamycinmainly consist of CCR7+, CD45RA+ TN-like cells (gated on live CD3+, CD4+ T cells) and exhibit a fraction of phenotypic CD95+, CD58+ TSCM cells with highest
frequencies in the transition zone (TZ). The ﬂow cytometry plot shows phenotypic TSCM cells in the total TN-like cell population. TSCM cell frequencies are depicted as percentages of the
deﬁned zones. Data are represented as mean ± SEM. FSC = forward scatter. SSC = side scatter. RZ = rand zone. TSCM = pharmacologically induced phenotypic TSCM cells. n = 5.
(c) Activation of highly puriﬁed human nCD4+ TN cells for 14 days in the presence of PP242 (100 nM) or KU-0063794 (100 nM) also leads to the formation of the small-sized
lymphocyte population (red arrows), containing phenotypic CD95+, CD58+ TSCM cells (shown in the total TN-like cell population). In contrast, priming in the presence of the alternative
Wnt activators Indirubin-3-monoxime (I-3-M, 4 μM) or Wnt3A (10 nM) does not lead to the formation of the small-sized lymphocyte population (red arrows). n = 4. TSCM =
pharmacologically induced phenotypic TSCM cells.
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Table 1
Relative percentages and absolute cell numbers of live CD4+ TN, TSCM and TCM cells in the
small-sized lymphocyte population. Numbers are presented as mean ± standard error of
the mean (SEM). n = 5.
Rapamycin TWS119
% Absolute % Absolute
TN 86.37 ± 1.02 181.429 ± 19.055 72.36 ± 10.71 120.956 ± 22.647
TSCM 7.97 ± 0.89 16.434 ± 2.175 11.79 ± 2.03 18.312 ± 1.827
TCM 2.54 ± 0.48 5.215 ± 967 5.23 ± 2.46 7.741 ± 3.287
54 G. Scholz et al. / EBioMedicine 4 (2016) 50–61assessed by ﬂow cytometry in highly puriﬁed human nCD4+ TN cells
(Fig. 2a) and nCD8+ TN cells (Fig. 2b) as well as by Western blot anal-
ysis for pS6 in highly puriﬁed human nCD4+ TN cells (Fig. 2c) upon ac-
tivation and drug interference.
Surprisingly, the Wnt activator TWS119, which was able to induce
phenotypic TSCM cells, also abolished the phosphorylation of S6
(Fig. 2a to c), suggesting an inhibitory effect of TWS119 onmTORC1. In-
terestingly, whereas the drugs which inhibitedmTORC1 (decrease of S6
phosphorylation)were also capable to induce phenotypic TSCM cells, the
drugs which activated Wnt (increase of pGSK-3β) did not induce phe-
notypic TSCM cells, suggesting that phenotypic TSCM cell induction isme-
diated by inhibition of mTORC1. In line with reports on differential
effects on S6 and 4EBP1 (Choo et al., 2008), TWS119 and rapamycin
had no signiﬁcant effects on p4EBP1, another protein downstream of
mTORC1, in nCD4+ TN cells (Fig. S2a) and nCD8+ TN cells (Fig. S2b).
Moreover, our results suggest that both TWS119 and rapamycin are
exerting amild, suboptimal effect onmTORC1 inhibition (S6K is blocked
but 4EBP1 is preserved, as is also mTORC2). Previous studies have dem-
onstrated that S6K is a more sensitive target of mTOR blockade than
4EBP1 (Chresta et al., 2010; Feldman et al., 2009). Thus, inhibition of
mTORC1 via decrease of S6 phosphorylation and independence from
Wnt signalling emerge as the molecular mechanisms which underlie
TSCM cell induction.
3.3. TWS119 Induces a Differentiation Arrest Independently From
Wnt Signalling
To conﬁrm this conclusion on a genetic base, we took advantage of
highly puriﬁed nCD4+ TN cells from mice with a haematopoietic dele-
tion of β- and γ-catenin, resulting in abolished Wnt signalling. In mice,
TSCM cells were phenotypically deﬁned by the expression of Sca-1
(Ly6A/E) and CXC chemokine receptor 3 (CXCR3) on naive-appearing
CD44−, CD62L+ T cells (Fig. S3a) (Gattinoni et al., 2009; Zhang et al.,
2005). Since mouse nCD4+ TN cells did not tolerate long drug treat-
ment phases, we needed to reduce priming periods to 4 days with
1.5 μM TWS119, an interval possibly too short to trigger an up-
regulation of TSCM cell markers. However, to conﬁrm its independence
from Wnt signalling, we hypothesised that under these conditions
TWS119 would at least arrest a fraction of activated β- and γ-catenin
KO nCD4+ TN cells in a TN-like state, in analogy to the formation of
the small-sized lymphocyte population observed in the in vitro experi-
ments with human nCD4+ TN cells. Interestingly, as observed for the
mTORC1 inhibitor rapamycin, this was also indeed the case for
TWS119, whereas the alternative Wnt activator SB216763 (2 μM),
which does not inhibit mTORC1, failed in doing so (Fig. 3 and Fig. 2c).
Thus, these data further conﬁrm that the mediation of a differentiation
arrest, as prerequisite for TSCM cell induction, is independent from
Wnt signalling, but dependent on mTORC1 inhibition. To further cor-
roborate these ﬁndings, we then assessed TSCM cell levels in the spleens
of β- and γ-catenin KO mice, using the above mentioned phenotype.
Suggesting no impairment in TSCM cell generation in the absence of
Wnt signalling, β- and γ-catenin KOmice exhibited naturally occurring
TSCM cells in comparable frequencies as their WT counterparts
(Fig. S3b). Furthermore, we took advantage of mice with a T cell-speciﬁc KO of the mTORC1 regulatory component Raptor, which leads
to an abolishment of mTORC1 signalling. Interestingly, supporting our
in vitro ﬁndings of rapamycin-mediated TSCM cell induction, we found
signiﬁcantly increased TSCM cell frequencies in these mice (Fig. S3c
and Fig. S3d). Moreover, excluding an off-target effect of rapamycin, ad-
ditional treatment of Raptor KO nCD4+ TN cells during 4-day priming
with rapamycin (100 nM) did not result in an increased fraction of
cells in a TN-like state (Fig. S3e). Altogether, these data present further
evidence for the inhibition of mTORC1 as themolecularmechanism un-
derlying TSCM cell induction.
3.4. Transcriptome Analysis of Naturally Occurring and Pharmacologically
Induced TSCM Cells
By transcriptome analysis, we next set out to assess the degree of re-
latedness between naturally occurring CD4+ TN, TSCM and TCM cells as
well as TWS119- and rapamycin-induced CD4+ TSCM cells to gain in-
sights into distinct proﬁles of gene expression in CD4+ TSCM cells. In
naturally occurring T cell subsets, unsupervised analysis showed a
very close relatedness between TSCM and TCM cells compared to TN
cells (Fig. 4a and b), potentially indicating a continuous transition
from TSCM to TCM cells during differentiation. Suggesting CD4+ T cell
differentiation as process which may be strictly regulated by a core set
of genes, only 895 genes were found to be signiﬁcantly differentially
expressed between TN and TSCM cells and 141 genes between TSCM and
TCM cells by supervised analysis (adj. p b 0.05; | log2FC| N 1) (Fig. 4c,
Table S2, Table S3). To identify further differences between TSCM and
TCM cells with respect to the stem cell-like nature of TSCM cells, we car-
ried out a gene set enrichment analysis for stem cell characteristic
genes (view Supplemental Information) and could identify FGFR1, RB1
and NOTCH2 to be highly expressed in TSCM cells in comparison to TCM
cells (adj. p = 0.07). Of further interest for the distinction of TSCM
from TCM cells, 18 genes were found to be signiﬁcantly differentially
expressed between these otherwise closely related subsets and not
shared by any other subset (Fig. 4c and Table 4). In addition, a set of
56 genes could be identiﬁed to be signiﬁcantly differentially expressed
between TN and TSCM cells and between TSCM and TCM cells, thus, show-
ing a unique expression proﬁle in TSCM cells (Fig. 4c and Table 2). Inter-
estingly, from these 56 genes only 4 genes, SLC22A17, RAI2, SALL2 and
LOC338651, were down-regulated in TSCM cells (Fig. S4a), whereas all
the other genes were up-regulated. Moreover, with exception of TCF4,
Wnt signalling transducers could be found to be highly expressed either
in both, TN and TSCM, or signiﬁcantly up-regulated in TN cells, further ar-
guing against the theory that activation of the Wnt pathway in TN cells
induces TSCM cells (Fig. S4b).
Interestingly, TWS119- and rapamycin-induced TSCM cells showed a
very close degree of relatedness. From 21,481 interrogated genes, only
565 genes were signiﬁcantly differentially expressed between them
(adj. p b 0.05; |log2FC| N 1), further supporting our ﬁnding of a common
pharmacological mechanism of these drugs (Fig. 4a to c and Table S5).
However, since TWS119- and rapamycin-induced TSCM cells have re-
ceived strong activating stimuli over 14 days, it was likely that their tran-
scriptomediffered from the ones of naturally occurring TSCM cells, directly
sorted ex vivo in their resting state. Nonetheless, we hypothesised that
the set ofwell-known factors of human effector andmemory T cell differ-
entiationwould showa comparable expression proﬁle in naturally occur-
ring and pharmacologically induced TSCM cells (Gattinoni et al., 2011).
Indeed, similar expression levels of the regulators of effector differentia-
tion CXCR3, KLRG1, PRDM1 and TBX21 could be found (Fig. 4d). Interest-
ingly, in vitro induced TSCM cells exhibited higher expression levels of
GZMA and PRF1 (Fig. 4d), probably equipping them with superior direct
effector functions. In vitro induced and naturally occurring TSCM cells
displayed a similar expression level of TNF, but, notably, in vitro induced
TSCM cells exhibited low IFNG expression levels (Fig. S4c). This might be
a result of IFNGdown-regulation due tomTORC1 inhibition, amechanism
described for type I interferons in plasmacytoid dendritic cells mediated
Fig. 2. TWS119 inhibits mTORC1. Assessment of phosphorylation of GSK-3β (Ser9) and of phosphorylation of S6 ribosomal protein (Ser235/236) by ﬂow cytometry in (a) highly puriﬁed
(TSCM cell-freed) nCD4+ TN cells and in (b) highly puriﬁed nCD8+ TN cells. n= 3. (c) Assessment of phosphorylation of S6 ribosomal protein (Ser235/236) byWestern blot technique in
highly puriﬁed nCD4+ TN cells. n = 3. Activation of TN cells in the presence of rapamycin (100 nM), PP242 (100 nM) and, of note, also of the Wnt activator TWS119 (5 μM) inhibits
mTORC1 signalling. In contrast, the alternative Wnt activators Indirubin-3-monoxime (I-3-M, 4 μM), Wnt3A (10 nM) and SB216763 (4 μM) do not reduce phosphorylation of S6.
NPA= no primary antibody. Beads = Anti-CD3/CD28 beads. TWS = TWS119. RAPA = rapamycin. MFI = median ﬂuorescence intensity.
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IRFs are involved in CD4+ T cell differentiation (Lohoff and Mak,
2005), and IRF7 was found to be up-regulated in in vitro induced
TSCM cells (Fig. S4c). Furthermore, similar expression levels of the
inhibitory factors for T cell activation and differentiation CERS6, EOMES,
LEF1, TAF4B and ACTN1 as well as for the TSCM cell characteristic factors
CD27, ITGAL, IL2RB and TNFSF9 could be identiﬁed (Fig. 4d). In addition,
the expression levels of genes encoding distinct interleukins are shown
in Fig. S4d. Finally, conﬁrming the purity of the performed cell sorts,
naturally occurring TN, TSCM and in vitro induced TSCM cells expressed
similarly low amounts of HNRPLL, a key regulator of the alternative
splicing of the CD45 pre-mRNA (Oberdoerffer et al., 2008). Additionally,
FAS was among the most signiﬁcantly differentially expressed genesbetween naturally occurring TN and TSCM cells (Fig. S4e). Altogether,
these data present insights into the transcriptional regulation of TSCM
cells and underline the pharmacological inhibition of mTORC1 as a
molecular mechanism to confer stemness to a population of activated
TN cells.
3.5. In Vitro Induced TSCM Cells Exhibit a Long-term Repopulation Capacity
in Vivo
The distinct up-regulation of transcripts encoding telomerase, anti-
apoptotic genes and positive cell cycle regulators and down-regulation
of pro-apoptotic genes and CDK inhibitors (Fig. S5a) (Igney and
Krammer, 2002; Vermeulen et al., 2003) suggested that in vitro induced
Fig. 3. TWS119 acts independently fromWnt. Both, TWS119 (1.5 μM) and rapamycin (100 nM), arrest a fraction of highly puriﬁed (TSCM cell-freed) wild-type (WT, β-cateninlox/lox γ-
cateninlox/lox, top) and β- and γ-catenin knockout (KO, β-cateninlox/lox γ-cateninlox/loxvav-cre, bottom) nCD4+ TN cells after 4 days of in vitro activation with anti-CD3 (2 μg/ml), anti-
CD28 antibody (2 μg/ml) and IL-2 (10 ng/ml). In contrast, SB216763 (2 μM) fails to mediate this differentiation arrest in activated WT and KO nCD4+ TN cells. TN-like cell frequencies
are depicted as percentages of live CD3+, CD4+ T cells. n = 3. Data are represented as mean ± SEM. ns = not signiﬁcant.
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We directly assessed this potential in vivo long-term persistence by
adoptive transfer of 200,000 rapamycin-induced CD4+ TSCM cells, iso-
lated to high purity by ﬂow cytometry-based cell sorting, into
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice. Ten weeks after adoptive
transfer, peripheral blood, spleen, bonemarrow, lung and liver were in-
vestigated by multicolour ﬂow cytometry for TSCM cell persistence
(Fig. 5a and Fig. S5b). Interestingly, in two of three experiments, the
spleens of the mice, which have received TSCM cells, showed the pres-
ence of a live CD3+, CD4+ T cell population with a CCR7−, CD45RA-
intermediate phenotype (Fig. 5a), indicating both, the potential of in vitro
induced CD4+ TSCM cells to persist long-term in vivo and their ability
to repopulate the effector pools by giving rise to further differentiated
progeny. In a third experiment, adoptively transferred TSCM cells yielded
live CD3+, CD4+ T cells in the peripheral blood ten weeks after adop-
tive transfer (Fig. 5a). In contrast, no T cells could be detected after
adoptive transfer of same numbers of TN-like or TCM-like cells, re-
sorted from the small-sized lymphocyte population from the same
in vitro cell culture (Fig. S5b). Spleen size and weight did not exhibit
any differences between the groups (Fig. S5b). Of note, compared to
naturally occurring CD4+ TN cells, in vitro induced CD4+ TSCM cells
showed an up-regulation of the haematopoietic stem cell engraftment
genes HOXA1 and LPXN (Powers and Trobridge, 2013), which might
have mediated their superior engraftment capacity (Fig. S5c). Together,
these data suggest a potential advantage of pharmacologically inducedCD4+ TSCM cells in mediating a prolonged immune response after
adoptive transfer. Of note, we did not observe signs of xeno-GVHD in
contrast to a report showing that rapamycin-treated T cells caused
more xeno-GVHD (Amarnath et al., 2010). Further studies are warrant-
ed to assess the relative functional features of rapamycin-induced TSCM
cells and their long-term repopulation capacity after adoptive transfer.
Next, the proliferative capacity of 30,000 rapamycin-induced CD4+
TSCM cells in comparison to equal numbers of TN-like and TCM-like cells,
re-sorted from the small-sized lymphocyte population from the same
in vitro cell culture, was assessed by CFSE dilution assay. T cells were ei-
ther left for 6 days in presence of IL-2 (50 IU/ml) or, additionally, stim-
ulated with OKT3 (1 μg/ml) and anti-CD28 antibody (10 μg/ml)
(Fig. 5b). Interestingly, in two of six experiments, stimulated in vitro in-
duced TSCM cells formed a small-sized resting T cell population in addi-
tion to a large proliferating one, probably reﬂecting their stem cell
nature, which is both, the capacity to self-renew and to differentiate
(Fig. 5b).
3.6. Substrate Utilization and Cellular Metabolism of TSCM Cells
Increasing evidence suggests that T cell differentiation is controlled
by ﬁne-tuned modulations of glycolysis and fatty acid oxidation (FAO)
(Cham et al., 2008; Fox et al., 2005; Zheng et al., 2009). To investigate
the predominance of a distinct metabolic programme in TSCM cells, we
next measured the uptake capacity of the ﬂuorescent glucose analogue
Fig. 4. Fate-determining key factors in naturally occurring andpharmacologically induced TSCM cells. Heatmapof gene expression among nCD4+TN cells, TSCM cells and TCM cells aswell as
TWS119- and rapamycin-induced CD4+TSCM cells. For interpretability, only the 1000 geneswith the highest average normalized count levels across all sampleswere included in the heat
map (Table S6). (b) Principal component analysis led to grouping of naturally occurring T cells on the one side and pharmacologically induced T cells on the other side by the ﬁrst two
principal components. In the ﬁrst group, TSCM cells and TCM cells are most similar to each other. The ﬁrst principle component captured a large fraction (35.5%) of the total variance in
the data. (c) Venn diagram depicting overlaps among signiﬁcantly differentially expressed genes found in pairwise comparisons between TN cells, TSCM cells and TCM cells. Numbers
indicate genes. The set of 56 genes is circled in red. (d) Comparative graphic representation of expression levels of naive/memory- and effector-associated genes in TN cells, TSCM cells,
TCM cells and TWS119- and rapamycin-induced TSCM cells. The y-axes show normalized counts. Data are based on transcriptome analysis in 4 healthy human individuals. D1–4 =
Donor 1–4. TN = TN cells. TSCM = TSCM cells. TCM = TCM cells. TWS = TWS119-induced TSCM cells. RAPA = rapamycin-induced TSCM cells.
57G. Scholz et al. / EBioMedicine 4 (2016) 50–612-NBDG in rapamycin-induced TSCM cells in comparison to TN-like, TCM-
like and TEM-like cells and to the respective naturally occurring T cell
subsets as reference point for glycolytic activity (Sukumar et al.,
2013b). Interestingly, compared to the divergent glucose uptake ofTEM cells and TEM-like cells, all other T cell subsets exhibited a limited
glucose uptake, suggesting especially for TSCM cells an independence
from glycolysis (Fig. 5c). In line, pharmacologically induced TSCM cells
also showed low expression of the gene encoding the master regulator
Table 2
56 genes shared between the sets of genes found to be
differentially expressed between the nCD4+ TN cell
and nCD4+ TSCM cell groups as well as between the
nCD4+ TSCM cell and nCD4+ TCM cell groups, but not
between the nCD4+ TN cell and nCD4+ TCM cell
groups.
Gene name
1. IKZF4
2. SWAP70
3. FAM49A
4. HLA-DPB1
5. COBLL1
6. FCRL1
7. FCER1G
8. HBA1
9. SELP
10. HLA-DMB
11. CCL4
12. IFI30
13. IGLL5
14. BTK
15. LAYN
16. HLA-DMA
17. PTPN3
18. NKG7
19. WDFY4
20. PHACTR1
21. ANKRD33B
22. CDK14
23. COL19A1
24. CCL3
25. FAM129C
26. TLR5
27. SERPINA1
28. GFOD1
29. ARHGAP24
30. BANK1
31. ADAM12
32. GZMB
33. ARAP3
34. SLC22A17
35. IGJ
36. RAI2
37. TYROBP
38. PRF1
39. CAV1
40. FHL3
41. CNR2
42. LOC100130357
43. SALL2
44. KIAA0226L
45. CYBB
46. CD22
47. MNDA
48. MT1L
49. ALAS2
50. LYN
51. FCRL2
52. MS4A1
53. LOC338651
54. SNCA
55. SETBP1
56. HBG2
58 G. Scholz et al. / EBioMedicine 4 (2016) 50–61of glycolytic enzymeHIFA (Fig. S5d). Alternatively, as reference point for
oxidative metabolism such as FAO, we measured the mitochondrial
membrane potential (MMP) in the mentioned T cell subsets by assess-
ment of their uptake of TMRE, a dye, which accumulates in active mito-
chondria of short-lived effectors (Sukumar et al., 2013a). Accordingly,
we could ﬁnd an increase of TMRE uptake going along with progressive
cellular differentiation (Fig. 5d).
Since these observations suggest that TSCM cells rather gain their en-
ergy from an oxidative metabolism, we hypothesised that FAO might
also be the relevant metabolic programme in the induction of TSCM
cells. We, therefore, investigated the impact of the pharmacologicalTSCM cell inducers TWS119 and rapamycin on the metabolism of
activated nCD4+ TN cells by assessment of ECAR, which is an indicator
of glycolytic activity, and OCR, which is an indicator of mitochondrial
respiration, by Seahorse analysis (Fig. 5e left). Interestingly, administra-
tion of TWS119 (5 μM) or rapamycin (100 nM) prevented the develop-
ment of full cellular glycolytic activity in response to oligomycin (1 μg/
ml), a drug, enforcing maximal glycolysis. Thus, we hypothesised that
TWS119 and rapamycin initiate ametabolic programme for TSCM cell in-
duction which is alternative to glycolysis. To disclose whether this
metabolic programmewould be FAO,we triggeredmitochondrial respi-
ration in rapamycin-pretreated (100 nM, 2 h) and activated nCD4+ TN
cells by administration of palmitate (500 μM), the ester of retinol and
palmitic acid. Interestingly, the presence of palmitate increased mito-
chondrial respiration to the levels measured in nCD4+ TSCM cells
(Fig. 5e right). Thus, these data present evidence for FAO as metabolic
programme characteristic of TSCM cells and needed for TSCM cell
induction.
4. Discussion
The identiﬁcation of the signalling pathways, underlying TSCM cell
formation, allows their targeted induction and paves theway for the de-
sign of novel immunotherapeutic approaches. Here, we show the emer-
gence of a T cell population with phenotypic, transcriptional, functional
and metabolic hallmarks of naturally occurring TSCM cells upon in vitro
inhibition of mTORC1 during priming of human TN cells. These ﬁndings
emphasize thepotential relevance of the signallingnetwork ofmTORki-
nase in immunotherapy and of mTOR modulating pharmacological
agents.
Interestingly, we show that mTORC1 inhibition with drugs like
rapamycin mediates an immunostimulatory effect by the induction of
TSCM cells, although these drugs are generally used because of their im-
munosuppressive function (Cobbold, 2013; Ferrer et al., 2011). Thus,
these observations indicate that there are distinct conditionswhich trig-
ger either a preferential immunostimulatory or an immunosuppressive
rapamycin effect. Among a variety of different molecular mechanisms,
rapamycin has been suggested to fulﬁl its immunosuppressive function
by prevention of full T cell activation (Loewith et al., 2002; Thomson
et al., 2009). This effect can be circumvented by strong stimulation of
the TCR and co-stimulatory receptors (Slavik et al., 2004). Similarly, in
the in vitro experiments the high degree of activation of TN cells by
anti-CD3/CD28 beads in a 1:1 bead/cell ratio and 300 IU/ml IL-2 might
have favoured an immunostimulatory rapamycin effect. Furthermore,
rapamycin has been shown to increase the antigen-speciﬁc T cell re-
sponse to a pathogen (short-term persistence of the antigen), but to
fail in doing so in response to a graft (long-term persistence of the anti-
gen) (Ferrer et al., 2010). Theseﬁndings strongly suggest that the period
of antigen persistence also regulates the immunological outcome of
rapamycin. Thus, the rather short periods of TN cell activation (14 days
and 4 days) in our in vitro experiments might have tipped the balance
towards an immunostimulatory rapamycin effect. The used concentra-
tion of rapamycin also emerges as an important factor for mediating ei-
ther an immunostimulatory or an immunosuppressive drug effect. For
the in vitro induction of TSCM cells, rapamycin was used in 100 nM
(90 ng/ml), since a rather high concentration of 40–100 ng/ml
rapamycin, administered during the contraction phase, has been
shown to qualitatively improve antigen-speciﬁc memory T cells in a
mouse model of CD8+ T cell response to acute viral infection (Araki
et al., 2009). In contrast, 8–12 ng/ml rapamycin blood levels are
intended to induce immunosuppression after transplantation (Baan
et al., 2005). Together, this suggests that a low rapamycin concentration
preferentially results in an immunosuppressive effect, whereas a high
rapamycin concentration triggers an immunostimulatory one. Also the
immunomodulatory actions of rapamycinmight be regulated by the in-
terplay between the two mTOR complexes. Whereas TSCM cell induc-
tion, as shown here, follows mTORC1 inhibition without additional
Fig. 5. In vivo long-term repopulation capacity and cellularmetabolism of CD4+ TSCM cells. (a) Live CD3+, CD4+ T cells with a CCR7−, CD45RA intermediate phenotype can be detected
in the spleen and peripheral blood of NSGmice, tenweeks after adoptive transfer of 200,000 rapamycin-induced CD4+ TSCM cells. Con= control: injection of 200 μl culture medium. The
grey underlay shows the distribution of CCR7 and CD45RA expression in live CD3+, CD4+ T cells in a healthy donor control. n = 3. (b) Rapamycin-induced CD4+ TSCM cells show a
proliferative proﬁle similar to the one of TCM-like cells. In two of six experiments, activated rapamycin-induced CD4+ TSCM cells formed an additional small-sized lymphocyte
population, which resisted to activating stimuli (red arrow). n = 6. (c) CD4+ TEM and TEM-like cells display a divergent glucose uptake capacity. In comparison, nCD4+ TN, TSCM and
TCM cells as well as rapamycin-induced CD4+ TSCM, TN-like and TCM-like cells do not show high 2-NBDG incorporation. n = 3. (d) Increase of mitochondrial membrane potential
(MMP), measured by TMRE uptake, goes along with progressive T cell differentiation. Administration of the oxidative decoupler FCCP leads to immediate MMP breakdown, proving
the T cells` viability. n = 3. (e) Top: Activation of nCD4+ TN cells with anti-CD3/CD28 beads increases ECAR (1). Administration of TWS119 (5 μM) or rapamycin (100 nM)
(2) hinders activated TN cells to fully develop glycolytic activity upon oligomycin (1 μg/ml) injection (3). n = 4. Bottom: Palmitate (500 μM) substitution increases the OCR in
rapamycin-pre-treated, activated TN cells to similar levels as the ones of nCD4+ TSCM cells. n = 3. Data are represented as mean ± SEM. ECAR = extracellular acidiﬁcation rate.
OCR = oxygen consumption rate. AUC = area under the curve. TN = TN cells. TSCM = TSCM cells. TCM = TCM cells. TEM = TEM cells. TN-like = TN-like cells. TCM-like = TCM-like cells.
TSCM RAPA = rapamycin-induced TSCM cells. RAPA = rapamycin. TWS = TWS119. BEADS = anti-CD3/CD28 beads.
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60 G. Scholz et al. / EBioMedicine 4 (2016) 50–61inhibition of mTORC2, formation of immunosuppressive regulatory T
cells is favoured in additional absence of mTORC2 signalling (Chi,
2012). Thus, immunomodulation by rapamycin appears to be a ﬁne-
tuned, highly multidimensional process.
Furthermore, we show that the induction of TSCM cells is completely
independent from theWnt signalling pathway. In linewith this, the role
ofWnt inmemory T cell formation has already been called into question
by reports about memory T cell formation in CD8+ T cells, in which β-
catenin was conditionally knocked out (Driessens et al., 2010; Prlic and
Bevan, 2011). Nevertheless, these reports have to be seen with caution,
since, in contrast to our study, speciﬁcally, TSCM cell formation was not
investigated and mice with KO of only β-catenin, which might have
favoured a bypassed activity of Wnt signalling by γ-catenin, were
used. Moreover, our data offer an unexpected answer to the paradox
ﬁnding that the Wnt activator TWS119 induces TSCM cells, whereas
none of alternative Wnt activators was able to do so, by the discovery
of an mTORC1 inhibiting effect of TWS119. Interestingly, this effect
ﬁnds further conﬁrmation by a recent report, conﬁrming in mouse
T cells that TWS119 inhibits mTORC1 (Xiao et al., 2013). At present, it
is unclear what the scope of TWS119 off-target effects on other kinases
is orwhether its inhibition of themTORC1kinase requires, as rapamycin,
FKBP12. Future biochemical and pharmacological studies will have to
address the precise molecular mechanism of mTORC1 inhibition by
TWS119.
We also showed that mTORC1 inhibition switched the metabolic
programme of activated nCD4+TN cells to an oxidativemetabolismde-
pendent on FAO.However, prominently, in the in vitro experiments only
a fraction of activated TN cells was arrested in a TN-like state by TWS119
or rapamycin, suggesting that not all TN cells from the phenotypically
homogenous CCR7+, CD45RA+ starting population react to mTORC1
inhibition in the sameway. Future studies will have to address whether
TN cell intrinsic factors can be identiﬁed which predispose certain cells
to stop differentiation upon mTORC1 inhibition. One such factor might
be Krüppel-like-factor 2 (KLF2) which has been shown to maintain
the expression of CCR7 and CD62L and has been suggested to be up-
regulated upon mTORC1 inhibition (Chi, 2012; van der Windt et al.,
2012). Interestingly, only a small fraction of the CCR7+, CD45RA+,
nCD4+ TN cell starting pool exhibited a high KLF2 expression, whereas
the vastmajority showed a lowexpression of KLF2 (Fig. S5e), suggesting
KLF2 as possible discriminator to delineate TN cells with TSCM cell pre-
cursor potential.
We sought to compare the transcriptome of CD4+ TSCM cells in-
duced by either TWS119 or rapamycin. Indeed, we observed a very
highly overlapping gene expression signature shared by rapamycin-
and TWS119-induced CD4+ TSCM cells. Among 21,481 interrogated
genes, only 565 genes were signiﬁcantly differentially expressed be-
tween them (adj. p b 0.05; |log2FC| N 1), further supporting a common
pharmacological mechanism of these drugs. It is very interesting that
several of the up-regulated genes in the rapamycin treatment group
were related with cell metabolism (Supplemental Table 5). Of note,
the most highly up-regulated gene with rapamycin induction is
NAD(P)H:quinone oxidoreductase (NQO1), which protects cells against
oxidative stress and toxic quinones. In linewith this, TXNRD1 (encoding
the thioredoxin reductase 1) was also up-regulated in rapamycin-
induced TSCM cells. This protein could reduce thioredoxins and plays
an important role in protection against oxidative stress. High expression
of NQO1 and TXNRD1might be closely relatedwith the increased oxida-
tive phosphorylation and fatty acid oxidation upon rapamycin induction
of TSCM, which deﬁnitely needs to be addressed further. On the other
hand, the most up-regulated gene in TWS119-induced TSCM cells is
LAMP3 (CD63). CD63 is barely expressed in naïve T cells but induced
upon T cell activation. Crosslinking of CD63 has been shown to deliver
a potent co-stimulatory signal to T cells. To our surprise, we noticed a
striking induction of interferon responsive gene expression pattern in
TWS119-induced TSCM cells (for example, interferon-induced protein
with tetratricopeptide repeats 2, IFIT2; Interferon-Induced Proteinwith Tetratricopeptide Repeats 3, IFIT3; interferon alpha-inducible pro-
teins 6, IFI6; interferon alpha-inducible proteins 27, IFI27). Many of
these genes have been shown to be important for antiviral innate im-
munity. Some of them emerge to play important roles in regulating T
cell activation and immune response. For instance, ISG15 protease
UBP43 (USP18) regulates T cell activation. USP18 deﬁcient T cells exhib-
it hyperactivation of NF-κB and NFAT upon TCR triggering and are de-
fective in Th17 differentiation. The roles of many of those genes in
regulating T cells immunity remain to be determined in the near future.
From a translational standpoint, TSCM cells emerge as most promis-
ing population for immunotherapy. In this regard, recent reports
which indicate that the efﬁcacy of CAR T cells might be based on their
acquisition of a TSCM cell phenotype are highly encouraging (Yang
et al., 2014); however, previous work showed that also other T cell pop-
ulations have the capacity to persist long-term in vivo (Berger et al.,
2008; Markley and Sadelain, 2010). Our data suggest the use of
rapamycin for efﬁcient in vitro TSCM cell induction or in vivo application
to enrich for antigen-speciﬁc TSCM cells, which should be performed
over a short period and by high drug concentration. However, the latter
approach will need clinical studies titrating rapamycin doses and
assessing different application time-points. Also our insights into TSCM
cell metabolism could be used for clinical purposes, since it seems to
be rational to provide glucose in treatment phases inwhich a strong im-
mune attack by TEFF cells is desired. In contrast, in periods of long-term
tumour control, in which T cells should enter low differentiation states,
substrates allowing FAO should be unrestrictedly provided. In addition,
future studies will have to assess the characteristics of and interplay be-
tween naturally occurring CD8+TSCM cells and CD4+TSCM cells aswell
as their rapamycin- and TWS119-induced counterparts in preclinical
and clinical in vivo settings.
Thus, cellular signalling and metabolism emerge as most promising
targets to inﬂuence TSCM cell differentiation for the design of innovative
immunotherapies.
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